Financial statements
Envision Pharma Trustee Limited

For the period ended 30 June 2017

TUESDAY

A6Z7HYKG

A12 06/02/2018 #137

COMPANIES HOUSE

Company No. 10214821

Company information

Company registration number	10214821
Registered office	Envision House 5 North Street Horsham West Sussex RH12 1XQ
Directors	G S Caswill J D Gillie S W Lyall-Cottle B S L Ladriere

Index

Report of the directors 3

Balance sheet 4

Notes to the financial statements 5

Report of the directors

The directors present their report and the financial statements of the company for the period from incorporation on 6 June 2016 to 30 June 2017.

Principal activities and business review

The company is a corporate trustee. The company has been dormant throughout the period and accordingly no profit and loss account has been prepared.

Directors

The directors who served the company during the year were as follows:

G S Caswill (appointed 6 June 2016)
J D Gillie (appointed 6 June 2016)
S W Lyall-Cottle (appointed 6 July 2016)
B S L Ladriere (appointed 6 July 2016)

On behalf of the Board

J D Gillie
Director

Date: 5 February 2018

Balance sheet at 30 June 2017

Company No. 10214821

	Note	2017 £
Current assets		
Debtors - amounts owed by group undertakings		1
Net current assets		1
Capital and reserves		
Called-up share capital	1	1
Shareholders' funds		1

For the period ended 30 June 2017 the directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 480, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and
ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial period and of its profit or loss for the financial period in accordance with the requirements of the Act, and which otherwise comply with the requirements of the Act relating to financial statements, so far as applicable to the company

These financial statements were approved by the directors on 5 February 2018 and are signed on their behalf by:

J D Gillie
Director

The accompanying accounting policies and notes form part of these financial statements.

Notes to the financial statements

1 Share capital

Authorised, allotted, called up and fully paid:

	2017 £
1 Ordinary shares of £1 each	1

At incorporation on 6 June 2016 the company issued 1 ordinary share of £1 at par.

2 Ultimate parent company

The ultimate parent undertaking is Envision Pharma Group Limited and the immediate parent undertaking is Envision Pharma Holdco Limited, a company incorporated in England and Wales which owns 100% of the issued share capital of this company.